GE Healthcare’s Pristina Recon DL received official rights to promote clear image quality

Announcement

GE Healthcare proudly confirmed that it has earned the FDA Premarket Authorisation for its modern 3D mammography image reconstruction technology, Pristina Recon DL. This commendable technology is sponsored by deep learning, setting a high standard bar in image clarity and definition. The tech approval in the vast healthcare sector is a precious win to boost confidence and earn the trust of patients and the healthcare professionals who are in a position to build a second thought.

Important tech support in the healthcare sector

Pristina Recon DL accelerates the two intense learning models aligned and operating in sequence to allow segregation of the noteworthy signal from the echo. The first model builds increased fidelity 3D volumes with super purity, with minimal artefacts and well-observed noise. The second model is designed to improve the visualisation of clinically suitable and convincing detail in the DL-synthesised 2D view.

The healthcare sector is aware of breast cancer as it is the most common cancer found in the female population, with around 1.1 million deaths registered under death care, and one in eight women has the chance to be diagnosed in their life span. The stress of this disease has opened the door for the advancement of AI-featured technologies that bring committed help to the accurate diagnosis, early detection and accelerating the quality of care.

Deep learning models specificity

The Pristina Recon DL is a modernised innovation to GE Healthcare’s robust Pristina Via™ system. It’s the first ever mammography technology to embed deep learning in its merger with iterative reconstruction to deliver a commendable digital breast tomosynthesis (DBT) image quality without sacrificing patient dose. Together, Pristina Recon DL with VIA uses NVIDIA RTX, an elevated computing technology, to implement its modern image reconstruction. This serves the appropriate, finest and fastest images in the exam hall and for specific clinical diagnosis (qualification).

The PhD, CEO and President of Women’s Health and X-ray at GE Healthcare, Jyoti Gupta, said, “Pristina Recon DL’s origin comes from an intense dedication and promise reserved for our customers through their valuable feedback and joining hands with radiologists to improve image clarity and quality. By using advanced deep learning technologies, we’re reframing the future of breast imaging, the one bond to accelerate workflows, and entitled to the superior confidence in early cancer detection and uncompromised image quality.”